Health Economics›Glioblastoma›Adjuvant therapy, standard patients

Adjuvant therapy, standard patients

Glioblastoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Lomustine, Temozolomide, RT Variant #01 Partial	—	R 2 453	42d	—	~48.1 mo	~6	~R 14 716 PFS proxy · indirect	1
RT, then Carmustine Variant #01 Partial	—	—	49d	—	—	~1	—	—

2 of 2 regimens shown